Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer

Nicole M. White, Shuang G. Zhao, Jin Zhang, Emily B. Rozycki, Ha X. Dang, Sandra D. McFadden, Abdallah M. Eteleeb, Mohammed Alshalalfa, Ismael A. Vergara, Nicholas Erho, Jeffrey M. Arbeit, Robert Jeffrey Karnes, Robert B. Den, Elai Davicioni, Christopher A. Maher

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Background Long noncoding RNAs (lncRNAs) are an emerging class of relatively underexplored oncogenic molecules with biological and clinical significance. Current inadequacies for stratifying patients with aggressive disease presents a strong rationale to systematically identify lncRNAs as clinical predictors in localized prostate cancer. Objective To identify RNA biomarkers associated with aggressive prostate cancer. Design, setting, and participants Radical prostatectomy microarray and clinical data was obtained from 910 patients in three published institutional cohorts: Mayo Clinic I (N = 545, median follow-up 13.8 yr), Mayo Clinic II (N = 235, median follow-up 6.7 yr), and Thomas Jefferson University (N = 130, median follow-up 9.6 yr). Outcome measurements and statistical analysis The primary clinical endpoint was distant metastasis-free survival. Secondary endpoints include prostate cancer-specific survival and overall survival. Univariate and multivariate Cox regression were used to evaluate the association of lncRNA expression and these endpoints. Results and limitations An integrative analysis revealed Prostate Cancer Associated Transcript-14 (PCAT-14) as the most prevalent lncRNA that is aberrantly expressed in prostate cancer patients. Down-regulation of PCAT-14 expression significantly associated with Gleason score and a greater probability of metastatic progression, overall survival, and prostate cancer-specific mortality across multiple independent datasets and ethnicities. Low PCAT-14 expression was implicated with genes involved in biological processes promoting aggressive disease. In-vitro analysis confirmed that low PCAT-14 expression increased migration while overexpressing PCAT-14 reduced cellular growth, migration, and invasion. Conclusions We discovered that androgen-regulated PCAT-14 is overexpressed in prostate cancer, suppresses invasive phenotypes, and lower expression is significantly prognostic for multiple clinical endpoints supporting its significance for predicting metastatic disease that could be used to improve patient management. Patient summary We discovered that aberrant prostate cancer associated transcript-14 expression during prostate cancer progression is prevalent across cancer patients. Prostate cancer associated transcript-14 is also prognostic for metastatic disease and survival highlighting its importance for stratifying patients that could benefit from treatment intensification.

Original languageEnglish (US)
Pages (from-to)257-266
Number of pages10
JournalEuropean urology
Volume71
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • Aggressive prostate cancer
  • Genomics
  • Long noncoding RNA
  • Metastases
  • PCAT-14
  • PRCAT-104
  • Transcriptome

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    White, N. M., Zhao, S. G., Zhang, J., Rozycki, E. B., Dang, H. X., McFadden, S. D., Eteleeb, A. M., Alshalalfa, M., Vergara, I. A., Erho, N., Arbeit, J. M., Karnes, R. J., Den, R. B., Davicioni, E., & Maher, C. A. (2017). Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. European urology, 71(2), 257-266. https://doi.org/10.1016/j.eururo.2016.07.012